LEVI GARRAWAY was named senior vice president, Global Development & Medical Affairs, for Eli Lilly and Co.‘s Oncology business. He will succeed Richard Gaynor, who is retiring, on Jan. 1, 2017. Garraway is an associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, an associate...
Early endpoints have the potential to get effective drugs to patients faster, but granting approval to drugs—even accelerated approval—comes with the risk that ineffective or even harmful drugs will be given to patients.
